These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22653493)

  • 1. [Direct antiviral treatment strategies in chronic hepatitis C].
    Neumann-Haefelin C; Blum HE; Thimme R
    Dtsch Med Wochenschr; 2012 Jun; 137(25-26):1360-5. PubMed ID: 22653493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hepatitis C virus: 25 years-old, the end?].
    Pol S
    Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.
    Chevaliez S
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S46-51. PubMed ID: 22248694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
    Pol S; Corouge M; Mallet V; Sogni P
    Minerva Gastroenterol Dietol; 2013 Jun; 59(2):161-72. PubMed ID: 23831907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C therapy in non-genotype 1 patients: the near future.
    Wartelle-Bladou C; Le Folgoc G; Bourlière M; Lecomte L
    J Viral Hepat; 2012 Aug; 19(8):525-36. PubMed ID: 22762136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiviral treatment of chronic hepatitis C].
    Berger A
    Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The race for interferon-free HCV therapies: a snapshot by the spring of 2012.
    De Clercq E
    Rev Med Virol; 2012 Nov; 22(6):392-411. PubMed ID: 22936636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New developments in HCV therapy.
    Kronenberger B; Zeuzem S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hepatitis C: perspectives.
    Pol S; Corouge M
    Med Mal Infect; 2014 Oct; 44(10):449-54. PubMed ID: 25174659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir for the treatment of hepatitis C.
    Forestier N; Zeuzem S
    Expert Opin Pharmacother; 2012 Mar; 13(4):593-606. PubMed ID: 22332992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.